BridgeBio Pharma
Tracked across 2 events · 17 articles · First seen Jun 11, 2026 · Last active Aug 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BridgeBio Pharma formed a strategic distribution partnership with DKSH to support regulatory evaluation and potential patient access to its transthyretin stabilizer for ATTR-CM in key Asia Pacific markets, leveraging DKSH's commercialization platform.
Jun 11, 2026 · 9 articles
Business
BridgeBio Pharma Pharma, Inc. announced the launch and subsequent pricing of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR & Co. Genetic Disorder L.P. The company is…
Impact: BridgeBio Pharma is the issuer of the shares being sold in the secondary offering. The company does not receive any proceeds, but the offering diversifies its shareholder base, which may be seen as a positive for long-term ownership stability.
Aug 13, 2026 · 8 articles
80
BridgeBio Pharma launched secondary offeringBridgeBio secondary offering by KKR
80
KKR & Co. sold shares BridgeBio PharmaBridgeBio secondary offering by KKR
ERGEN INTELLIGENCE
Track BridgeBio Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard